CANENCIA MALDONADO, F.; LOPEZ MORAN, MJ.; APARICIO HERNANDEZ, R.    GARCIA LUQUE, A.. Possitive assessment of drugs: December 2016, January and February 2017. []. , 73, 2, pp.100-106. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712017000200005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in December of 2016, January and February of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

: Adalimumab, (Amgevita^®); Adalimumab, (Solymbic^®); Alectinib, (Alecensa^®); Ciclosilicato de Circonio de Sodio, (Lokelma^®); Clormetina, (Legada^®); Etanercept, (Lifmior^®); Hormona Paratiroidea, (Natpar^®); Metotrexato, (Jylamvo^®); Rituximab, (Truxima^®); Rolapitant, (Varudy^®); Tofacitinib, (Xeljanz^®).

        · |     · |     · ( pdf )